Comparison Histamine-2 Receptor Antagonist & Antacid

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 5

Comparison Histamine-2 Receptor Antagonist &

Antacid
Histamine-2 Receptor Antagonist
 Their onset is slower than that of antacids, but their duration is
longer.
 In large heartburn studies the earliest onset of symptom relief
occurs around 30 minutes and peak effects are 1-1.5 hours after
treatment.
 The anti-secretory effect, even with low doses, is prolonged and
lasts for around 10-12 hours. This means dosing frequency compared
to antacids can be reduced and many subjects require only one dose
per day.

Antacid
 Acid in the oesophagus and stomach may be partly or completely
neutralised for rapid relief of symptoms but further gastric acid
production will occur and may be stimulated via a gastrin-mediated
response to a rise in gastric pH.
 The consumption of further food will contribute to the termination
of activity as gastric acid production is stimulated.
 By virtue of their mode of action, antacids cannot be used to
prevent symptoms associated with ‘trigger’ foods.
 For these reasons antacids require regular re-dosing as
symptoms return.
HISTAMINE-2 RECEPTOR
ANTACIDS
ANTAGONISTS
(Magnesium Trisilicate)
(Ranitidine)
Mechanism of Inhibit acid secretion by Antacids can neutralize
Action blocking H2 receptors on the gastric acid and reduce acid
parietal cell delivery to the
duodenum. They may also
stimulate the defensive
systems in the stomach by
increasing bicarbonate and
mucus secretion.
Side Effects Side effects of H2RAs are Antacid side effects depend
rare upon the quantity consumed
and the duration of therapy.
A common side effect
associated with ranitidine is Magnesium-containing
headache, occurring in about antacids cause diarrhea and
3% of people who take it. hypermagnesemia; the latter
only becomes important in
Confusion: Rare cases of patients with renal
reversible confusion have insufficiency.
been associated with
ranitidine; usually elderly or Long-term, excessive use has
severely ill patients, or in been associated with the
patients with renal or hepatic development of silica-based
impairment. renal calculi.

Hepatic effects: Elevation in


ALT levels has occurred with
higher doses (≥100 mg) or
prolonged IV therapy (≥5
days); monitor ALT levels
daily for the remainder of
treatment.

Vitamin B12 deficiency:


Prolonged treatment (≥2
years) may lead to vitamin
B12 malabsorption and
subsequent vitamin
B12 deficiency

Rebound acid hypersecretion


has been reported after
discontinuation of therapy.
Special Relief of symptoms does not May alter absorption of other
Precautions preclude the presence of a drugs, therefore
gastric malignancy. antacids, tetracyclines or iron
salts should be given 1-2
hours apart.
Use with caution in patients
with hepatic impairment At high dosage, magnesium
(ranitidine undergoes hepatic salts not only
metabolism). cause diarrhoea but also
Ranitidine is primarily possible CNS depression.
excreted renally; dosage
adjustment is recommended Magnesium trisilicate mixture
in patients with renal has a sodium content of 6.4
impairment. mmol equivalent to 73.4
mg/5 ml or 147mg/10 ml
dose. This must be taken into
consideration for patients on
a controlled sodium diet.
Used with caution in patients
with fluid retention

There is a risk of metabolic


alkalosis when oral
magnesium salts are given
with polystyrene
sulphonate resins.
Effectiveness Hotz et al, 1994
 With ranitidine, acid-related as well as general
dyspeptic symptoms disappeared in a significantly higher
percentage after two and four weeks compared with antacid.
 Complete disappearance of symptoms was
documented with ranitidine after two weeks in 37% and
after four weeks in 66% compared with antacid in 13% and
30% respectively (p < 0.005).
 Patients with severe symptoms, history of ulcer and
long-term dyspepsia and slight endoscopic changes in the
upper gastrointestinal tract showed a significant faster and
more distinct response. Both kinds of treatment were well
tolerated

References
1. https://www.uptodate.com.
2. http://www.kck.usm.my/husm/pharmacy/formulary/5.htm
#5a
3. https://www.uspharmacist.com/article/updates-in-
nonprescription-therapy-for-heartburn-and-gerd
4. https://www.ncbi.nlm.nih.gov/pubmed/8164599
5. http://selfcarejournal.com/article/self-care-of-heartburn/
6. https://www.drugs.com/ppa/ranitidine.htm
7. https://www.medicines.org.uk/emc/medicine/25289
8. http://www.nytimes.com/health/guides/disease/gastroesop
hageal-reflux-disease/medications.html
Posted by AskUsAtDis at 4:01 PM
Email ThisBlogThis!Share to TwitterShare to FacebookShare to Pinterest
Labels: Indication, others
1 comment:
1.

creative peptidesOctober 11, 2018 at 9:20 PM

Potent and selective amylin receptor antagonist that displays 38-


fold and 400-fold selectivity over calcitonin and CGRP receptors
respectively. Through attenuating the activation of initiator and
effector caspases in vitro, it blocks amyloid β-induced
neurotoxicity. AC 187
Reply

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy